Guest guest Posted November 23, 2008 Report Share Posted November 23, 2008 Hi Bobby, I found this ASH abstract on the XL228 drug and thought you might like to read it: http://ash.confex.com/ash/2008/webprogram/Paper13204.html I don't think it says anything you don't already know but for others who may want to know, the infusion is for patients who have already failed (either become resistant or intolerant to) at least two standard therapies (Gleevec, Sprycel or Tasigna). The majority of the patients have some type of mutation, with T315I, F317L and V299L being the most common. Most common side effects are fainting, fatigue, nausea, vomiting, slow heart rate and high glucose levels (interesting that they don't mention the numb tongue Bobby). The half life of the drug is 15-38 hours. The results are very preliminary as this is just a phase I trial but so far it looks promising, especially for those with the dreaded T315I mutation. Tracey Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.